A61P 5/04
For decreasing, blocking or antagonising the activity of the hypothalamic hormones
Official title: for decreasing, blocking or antagonising the activity of the hypothalamic hormones
A61P5/04 (For decreasing, blocking or antagonising the activity of the hypothalamic hormones) appears on 150 US grants and 226 published applications in this corpus.
Search patents in A61P- Granted patents
- 150
- Published applications
- 226
- Assignees
- 117
- Inventors
- 465
- Latest grant
- 31 Mar 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1996 | 1 | 0 |
| 1997 | 0 | 0 |
| 1998 | 5 | 0 |
| 1999 | 1 | 0 |
| 2000 | 2 | 0 |
| 2001 | 8 | 0 |
| 2002 | 6 | 14 |
| 2003 | 7 | 13 |
| 2004 | 10 | 20 |
| 2005 | 8 | 18 |
| 2006 | 13 | 16 |
| 2007 | 12 | 19 |
| 2008 | 11 | 8 |
| 2009 | 4 | 17 |
| 2010 | 5 | 11 |
| 2011 | 8 | 12 |
| 2012 | 7 | 7 |
| 2013 | 8 | 9 |
| 2014 | 6 | 4 |
| 2015 | 4 | 7 |
| 2016 | 6 | 11 |
| 2017 | 2 | 3 |
| 2018 | 2 | 5 |
| 2019 | 2 | 5 |
| 2020 | 4 | 3 |
| 2021 | 1 | 3 |
| 2022 | 2 | 5 |
| 2023 | 2 | 10 |
| 2024 | 1 | 4 |
| 2025 | 1 | 0 |
| 2026 | 1 | 2 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Reprogramming of lipid metabolism to inhibit T cell senescence and enhance tumor immunotherapy31 Mar 2026US 12,590,309 B2Saint Louis University
- Pharmaceutical compositions29 Apr 2025US 12,285,460 B2Rhythm Pharmaceuticals, Inc.
- Supplement for mitigating woman's disorders caused by ageing11 Jun 2024US 12,005,075 B2Cristalfarma S.R.L.
- Bispecific antigen binding molecules that bind leptin receptor and/or GP130, and methods of use thereof5 Dec 2023US 11,834,500 B2Regeneron Pharmaceuticals, Inc.
- Methods of treating or preventing estrogen-related diseases14 Feb 2023US 11,576,891 B2Endorecherche, Inc.
- Steroid as a modulator of gabaa receptor11 Jun 2026US 2026/0158043 A1Umecrine Cognition AB
- Pharmaceutical compositions26 Feb 2026US 2026/0053885 A1Rhythm Pharmaceuticals, Inc.
- Melatonin agonist treatment3 Oct 2024US 2024/0325339 A1Vanda Pharmaceuticals Inc.
- Applications of GHR-106 Monoclonal Antibody as a GnRH Antagonist20 Jun 2024US 2024/0199754 A1Vancouver Biotech Ltd.
- Bispecific antigen binding molecules that bind leptin receptor and/or gp130, and methods of use thereof16 May 2024US 2024/0158497 A1Regeneron Pharmaceuticals, Inc.
Most cited
By later US patents
- Polymeric delivery formulations of leuprolide with improved efficacy158US 6,773,714 B2Atrix Laboratories, Inc. · 2004
- Polymeric delivery formulations of leuprolide with improved efficacy132US 6,565,874 B1Atrix Laboratories, Inc. · 2003
- Screening and therapeutic methods for promoting wakefulness and sleep121US 6,884,596 B2The Regents of the University of California · 2005
- Sustained release compositions, process for producing the same and utilization thereof103US 6,740,634 B1Takeda Chemical Industries, Ltd. · 2004
- Anti-integrin antibodies, compositions, methods and uses101US 7,163,681 B2Centocor, Inc. · 2007